Saturday, 2 August 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 02 August 2025
News

Pharmas reel from $215M PBS cut

Posted 1 August 2025 AM

More than $215 million has been knocked off future PBS earnings, as a deal between Arrotex and South Korea's Celltrion sees two blockbusters face biosimilar competition - one for the first time - while Sandoz takes aim at another blockbuster market.

The two franchises hit with the statutory 25 per cent price reduction from today have a combined PBS earnings of $874.5 million a year, leaving Johnson & Johnson and Amgen significantly lighter in the pocket.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.